REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Show:
Income statement
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2019
31/12/2018
31/12/2017
31/12/2016
Total revenue
8,319,000
7,863,400
6,710,800
5,872,227
4,860,427
Cost of revenue
827,400
782,200
434,100
397,061
299,694
Gross profit
7,491,600
7,081,200
6,276,700
5,475,166
4,560,733
Operating expenses
Research development
3,134,400
3,036,600
2,186,100
2,075,142
2,052,295
Selling general and administrative
1,911,000
1,834,800
1,556,200
1,320,433
1,177,697
Total operating expenses
5,061,700
4,871,400
3,742,300
3,395,575
3,229,992
Operating income or loss
2,429,900
2,209,800
2,534,400
2,079,591
1,330,741
Interest expense
28,600
30,200
28,200
25,119
7,195
Total other income/expenses net
150,300
249,500
47,300
24,039
6,269
Income before tax
2,551,600
2,429,100
2,553,500
2,078,511
1,329,815
Income tax expense
272,300
313,300
109,100
880,000
434,293
Income from continuing operations
2,279,300
2,115,800
2,444,400
1,198,511
895,522
Net income
2,279,300
2,115,800
2,444,400
1,198,511
895,522
Net income available to common shareholders
2,279,300
2,115,800
2,444,400
1,198,511
895,522
Basic EPS
-
-
22.65
11.27
8.55
Diluted EPS
-
-
21.29
10.34
7.70
Basic average shares
-
-
107,900
106,338
104,719
Diluted average shares
-
-
114,800
115,954
116,367
EBITDA
-
2,669,600
2,729,900
2,249,097
1,441,755